Silo Pharma (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the company's common stock. The program allows purchases on the open market, through privately negotiated transactions, or other means, in compliance with SEC rules and applicable legal requirements. As of November 13, 2025, the company reported 13,318,273 shares of common stock outstanding, according to its quarterly report for the period ended September 30, 2025.
The timing and amount of any repurchases will depend on market conditions and corporate and regulatory limitations. The program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at its discretion. This initiative underscores management's belief that the company's stock is undervalued and represents a prudent use of capital to enhance shareholder value.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
For more details on the share repurchase program, view the full press release at https://ibn.fm/gU3uZ. The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO.
This announcement is significant as it signals management's confidence in the company's future prospects and its commitment to returning value to shareholders. Share repurchase programs can also help support the stock price during periods of market volatility. Investors will be watching to see how the company executes the program and whether it will have a positive impact on earnings per share over time.
